Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152315 | 0.89 | GSK3B (0.57) | GSK3BEGLN1RAB9AHIF1A | |
| SCHEMBL4148226 | 0.89 | GSK3B (0.49) | GSK3BEGLN1 | |
| SCHEMBL4147630 | 0.88 | GSK3B (0.49) | GSK3BEGLN1 | |
| SCHEMBL4153463 | 0.86 | GSK3B (0.41) | GSK3BEGLN1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4161415 | 0.85 | GSK3B (0.51) | GSK3B | |
| SCHEMBL4157386 | 0.83 | GSK3B (0.59) | GSK3BEGLN1RAB9AHIF1A | |
| SCHEMBL4151960 | 0.83 | GSK3B (0.64) | GSK3BEGLN1RAB9AHIF1AALDH1A1 | |
| SCHEMBL4152082 | 0.83 | GSK3B (0.48) | GSK3BEGLN1HIF1A | |
| SCHEMBL4169212 | 0.83 | GSK3B (0.38) | GSK3BALDH1A1 | |
| SCHEMBL4152720 | 0.82 | GSK3B (0.62) | GSK3BEGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | claimed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | GSK3B 1/4885EGLN1 3684/4885RAB9A 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.